PHARMARON BEIJING H YC1
Pharmaron Beijing Co., Ltd., together with its subsidiaries, operates as a pharmaceutical research and development service platform in North America, Europe, the Mainland China, Asia, and internationally. It operates through five segments: Laboratory Services; Chemical and Formulation Process Development and Production Services; Clinical Research Services; Macromolecule and Cell and Gene Therapy … Read more
Market Cap & Net Worth: PHARMARON BEIJING H YC1 (17Q1)
PHARMARON BEIJING H YC1 (F:17Q1) has a market capitalization of $20.56K (€20.03K) as of March 18, 2026. Listed on the F stock exchange, this Germany-based company holds position #4275 globally and #418 in its home market, demonstrating a 2.94% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying PHARMARON BEIJING H YC1's stock price €2.10 by its total outstanding shares 9538 (9.54K).
PHARMARON BEIJING H YC1 Market Cap History: 2019 to 2026
PHARMARON BEIJING H YC1's market capitalization history from 2019 to 2026. Data shows growth from $16.12K to $20.56K (3.99% CAGR).
PHARMARON BEIJING H YC1 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how PHARMARON BEIJING H YC1's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of 17Q1 by Market Capitalization
Companies near PHARMARON BEIJING H YC1 in the global market cap rankings as of March 18, 2026.
Key companies related to PHARMARON BEIJING H YC1 by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
PHARMARON BEIJING H YC1 Historical Marketcap From 2019 to 2026
Between 2019 and today, PHARMARON BEIJING H YC1's market cap moved from $16.12K to $ 20.56K, with a yearly change of 3.99%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €20.56K | +0.96% |
| 2025 | €20.36K | +21.64% |
| 2024 | €16.74K | +8.28% |
| 2023 | €15.46K | -68.40% |
| 2022 | €48.94K | -26.53% |
| 2021 | €66.60K | -0.43% |
| 2020 | €66.89K | +314.95% |
| 2019 | €16.12K | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of PHARMARON BEIJING H YC1 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $20.56K USD |
| MoneyControl | $20.56K USD |
| MarketWatch | $20.56K USD |
| marketcap.company | $20.56K USD |
| Reuters | $20.56K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.